Pazopanib, an orally administered VEGFR inhibitor approved for renal cell carcinoma and soft tissue sarcoma that inhibits all VEGF receptors subtypes, was found to cause signs and symptoms of anterior segment toxicity, comprising ocular irritation, dry eyes, keratitis, and chemosis [115]. This evidence concerns the gene KDR and soft tissue sarcoma.